[Skip to Content]
[Skip to Content Landing]
Views 171
Citations 0
Invited Commentary
November 17, 2016

Association of Molecular Marker Status With Graded Prognostic Assessment of Lung Cancer With Brain Metastases

Author Affiliations
  • 1Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
  • 2Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio
  • 3Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, Ohio
JAMA Oncol. Published online November 17, 2016. doi:10.1001/jamaoncol.2016.3818

Historically, the prognosis for patients with brain metastases was thought to be uniformly poor, which led to a purely palliative approach to treating the many patients diagnosed with this very common neurologic complication of cancer. In addition, brain metastases were previously considered a homogeneous disease, despite the myriad of tumors that could potentially spread to the brain and the observed variability in response to local and systemic therapies. Because physicians believed that the vast majority of patients with brain metastases would have uniformly poor outcomes, they adopted whole-brain radiation therapy (WBRT) as the standard of care: it is easy to administer, widely available, and effective at providing palliation.

First Page Preview View Large
First page PDF preview
First page PDF preview